Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1220

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Tremelimumab
DRUG: Rilvegostomig
DRUG: Bevacizumab
DRUG: Atezolizumab

Sponsor

AstraZeneca